Wilmington Savings Fund Society FSB Acquires 13,437 Shares of Novo Nordisk A/S (NYSE:NVO)

Wilmington Savings Fund Society FSB raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 86.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 28,999 shares of the company’s stock after acquiring an additional 13,437 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Novo Nordisk A/S were worth $3,453,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Sfmg LLC grew its stake in shares of Novo Nordisk A/S by 15.0% during the third quarter. Sfmg LLC now owns 1,815 shares of the company’s stock worth $216,000 after purchasing an additional 237 shares during the period. World Investment Advisors LLC boosted its holdings in Novo Nordisk A/S by 36.9% during the third quarter. World Investment Advisors LLC now owns 13,925 shares of the company’s stock worth $1,655,000 after buying an additional 3,750 shares during the last quarter. Sanctuary Advisors LLC grew its position in shares of Novo Nordisk A/S by 0.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 292,889 shares of the company’s stock worth $34,874,000 after buying an additional 1,130 shares during the period. Anchor Investment Management LLC increased its stake in shares of Novo Nordisk A/S by 2.3% in the 3rd quarter. Anchor Investment Management LLC now owns 13,447 shares of the company’s stock valued at $1,601,000 after acquiring an additional 297 shares during the last quarter. Finally, Tudor Financial Inc. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $311,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of analyst reports. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $150.40.

Novo Nordisk A/S Trading Down 1.5 %

Shares of NYSE:NVO opened at $106.96 on Friday. The firm has a market cap of $479.99 billion, a price-to-earnings ratio of 34.61, a PEG ratio of 1.43 and a beta of 0.40. Novo Nordisk A/S has a 12 month low of $96.53 and a 12 month high of $148.15. The company’s fifty day simple moving average is $110.59 and its 200 day simple moving average is $126.27. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.